APOE and Alzheimer disease: Among other drugs that showed promise in hiPSC-based AD models is the small molecule, PH002, which changes the conformation of APOE4 to resemble the conformation of APOE3, leading to the restoration of physiological Aβ40/Aβ42 ratios and decreased pTau levels [102].